Navigation Links
Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
Date:3/17/2008

ATLANTA and BOSTON, March 17 /PRNewswire-FirstCall/ -- Alimera Sciences and pSivida Ltd (Nasdaq: PSDV; ASX: PSD; Xetra: PSI) today announced that they have amended their license and collaboration agreement relating to Medidur(TM) FA, the companies' Phase III investigative treatment for diabetic macular edema (DME), and other Medidur products. Alimera is increasing its equity in the future profits of Medidur FA from 50 to 80 percent in exchange for consideration of up to approximately $78m to pSivida.

Consideration to pSivida includes an up-front payment of $12m, a $25m milestone payment upon FDA approval of Medidur(TM) FA, other payments of up to approximately $21m by September 30, 2012, and assumption of pSivida's research and development funding obligations estimated at approximately $20m.

"We are very pleased with this agreement as it provides us with the opportunity to increase our stake and consolidate the development and commercialization of our late stage DME product Medidur FA," said Dan Myers, President and CEO of Alimera Sciences. "In addition, we will further advance the delivery system's application in other serious ophthalmic conditions like dry age-related macular degeneration (AMD), using exploratory treatments such as the groundbreaking work we are doing around NADPH oxidase inhibitors."

"We believe this is a great deal for pSivida and its shareholders as it gives the company a significant financial interest in very exciting products and economics that eliminate our need for equity financing for the foreseeable future under our current plans," said pSivida Managing Director, Dr. Paul Ashton. "This new agreement with Alimera Sciences is expected to significantly reduce our burn rate going forward as the
'/>"/>

SOURCE Alimera Sciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
2. Pressure BioSciences, Inc. to Discuss 2007 Financial Results and Provide Business Update
3. DARA BioSciences, Inc. Announces Appointment of New Director to Board
4. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
5. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
6. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
7. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
8. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
9. Pressure BioSciences, Inc. Provides Corporate Update
10. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Dr. Greg Leyer of UAS Labs ... Natural Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... continuing education conference for health care professionals. This year’s pre-conference ... of probiotics in health. Dr. Leyer spoke about the emerging ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI ) ... results on Thursday, August 6, 2009. OncoGenex will host a ... afternoon to discuss quarterly results. , The webcast can be ... site at www.oncogenex.com . Alternatively, you may access the ...
... , ORANGE COUNTY, Calif., Aug. 2 ... developer, manufacturer and marketer of products that simplify, automate and ... acquisition of Olympus, lab-based diagnostics business. This acquisition, first ... and Automation. , , (Logo: ...
... team has developed a mathematical and cartographical model that make ... aftermath of forest fires. In order to carry out this ... & Software , the authors studied a Special Protection Area ... have developed a model that shows on maps how various ...
Cached Biology Technology:Beckman Coulter Completes Acquisition of Olympus' Lab-Based Diagnostics Business 2Model predicts evolution of Mediterranean landscape following fires 2
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced ... 2015-2019" report to their offering. ... a technology used for the identification of individuals. Facial ... person such as nose, jaw edges, mouth, and the ...
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market is ... utilize more than one characteristic of an individual for ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... promising alternative for the reconstitution of lost ... complications associated with traditional transplants. Tissue engineers ... by using engineered tissue substitutes that can ... into the host tissue. The traditional tissue-engineering ...
... After disappearing from Ontario due to over hunting in ... province thanks to the efforts of the Ontario elk ... success, published in the March issue of Restoration Ecology, ... various Ontario sites between 1998 and 2001. , "The ...
... to rivals with a visual display "shout" to get their ... lizards signal ownership of their territory by sitting up on ... extending a colorful throat pouch. They can spot a rival ... postdoctoral researcher at UC Davis who is working with Judy ...
Cached Biology News: